{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T10:17:48Z","timestamp":1772533068083,"version":"3.50.1"},"reference-count":54,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/132751\/2017"],"award-info":[{"award-number":["SFRH\/BD\/132751\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["DFA\/BD\/6038\/2020"],"award-info":[{"award-number":["DFA\/BD\/6038\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MEC-URO\/29043\/2017"],"award-info":[{"award-number":["PTDC\/MEC-URO\/29043\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>TGCTs represent a model of curable disease afflicting especially young men. Defining tumor biological characteristics is crucial to increase current knowledge and tailor the best clinical management. Ki67, a potential prognostic marker, still exhibits heterogenous associations with patient outcomes, thus bringing the need of corroboration with larger cohorts in clinical practice. LSD1, an epigenetic enzyme, represents a future target for epigenetic drugs that may lower treatment-associated morbidity. This study aimed to assess Ki67\/LSD1 immunoexpression across all TGCT histological subtypes and correlate it with clinicopathological features. Results were compared with an in silico analysis of the TCGA database. Immunohistochemistry for Ki67 and LSD1 was carried out in a cohort of 157 TGCT tumor samples and assessed using a digital pathology algorithm. LSD1 protein expression was explored in TGCT cell lines, including ATRA-differentiated clones. There was a significant positive correlation between Ki67 and LSD1 H-scores (rs = 0.182, p = 0.037). Ki67 positivity percentage and H-score were significantly higher in non-seminomas (p = 0.0316 and 0.0113, respectively). Expression was not significantly different according to clinicopathological features, including stage, IGCCCG prognosis-based system, or relapse\/progression-free survival, which was corroborated by in silico analysis. Our study, making use of digital image analysis, does not confirm the utility of these biomarkers in a daily practice cohort. Although not affecting patient outcome in our cohort, LSD1 is expressed overall in TGCTs, suggesting sensitivity to LSD1 inhibitors.<\/jats:p>","DOI":"10.3390\/life12020264","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T02:35:51Z","timestamp":1644546951000},"page":"264","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ki67 and LSD1 Expression in Testicular Germ Cell Tumors Is Not Associated with Patient Outcome: Investigation Using a Digital Pathology Algorithm"],"prefix":"10.3390","volume":"12","author":[{"given":"Beatriz Chaves","family":"Louren\u00e7o","sequence":"first","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal"}]},{"given":"Catarina","family":"Guimar\u00e3es-Teixeira","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-6309","authenticated-orcid":false,"given":"Bianca C. T.","family":"Flores","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4231-5532","authenticated-orcid":false,"given":"Vera","family":"Miranda-Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2013School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"given":"Rita","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal"}]},{"given":"Mariana","family":"Cantante","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal"}]},{"given":"Paula","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal"}]},{"given":"Isaac","family":"Braga","sequence":"additional","affiliation":[{"name":"Department of Urology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal"}]},{"given":"Joaquina","family":"Maur\u00edcio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2013School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2013School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2013School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"ref_1","unstructured":"National Comprehensive Cancer Network (2021, December 10). Testicular Cancer NCCN Clinical Pratice Guidelines in Oncology; Version 1.2022; 2021, NCCN Clinical Practice Guidelines in Oncology. Available online: www.nccn.org."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lobo, J., Gillis, A.J.M., Jeronimo, C., Henrique, R., and Looijenga, L.H.J. (2019). Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020258"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/andr.12814","article-title":"p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome","volume":"8","author":"Lobo","year":"2020","journal-title":"Andrology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/15592294.2020.1805682","article-title":"Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours: Current and future application of \u2018epidrugs\u2019","volume":"16","author":"Cardoso","year":"2021","journal-title":"Epigenetics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/epi-2016-0081","article-title":"The epigenetics of testicular germ cell tumors: Looking for novel disease biomarkers","volume":"9","author":"Costa","year":"2017","journal-title":"Epigenomics"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lobo, J., Rodrigues, A., Guimaraes, R., Cantante, M., Lopes, P., Mauricio, J., Oliveira, J., Jeronimo, C., and Henrique, R. (2019). Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1\/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. Cancers, 11.","DOI":"10.3390\/cancers11101535"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1097\/PAS.0000000000001352","article-title":"Interobserver Agreement in Vascular Invasion Scoring and the Added Value of Immunohistochemistry in Stage I Testicular Nonseminoma","volume":"43","author":"Lobo","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lobo, J., Gillis, A.J.M., van den Berg, A., and Looijenga, L.H.J. (2020). Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: Investigation of biomarkers. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07220-6"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.0.CO;2-S","article-title":"Distinct p53-Independent Apoptotic Cell Death Signalling Pathways In Testicular Germ Cell Tumour Cell Lines","volume":"81","author":"Burger","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.eururo.2017.09.025","article-title":"Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: A Systematic Review by the Testicular Cancer Guidelines Panel","volume":"73","author":"Boormans","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/j.clgc.2018.10.007","article-title":"Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer","volume":"17","author":"Leao","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lobo, J., Jeronimo, C., and Henrique, R. (2020). Targeting the Immune system and Epigenetic Landscape of Urological Tumors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030829"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1078-0432.CCR-15-1186","article-title":"Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma","volume":"22","author":"Gilbert","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer","volume":"25","author":"Gietema","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.18.01250","article-title":"Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance","volume":"37","author":"Hamilton","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pulzova, L.B., Roska, J., Kalman, M., Kliment, J., Slavik, P., Smolkova, B., Goffa, E., Jurkovicova, D., Kulcsar, L., and Leskova, K. (2021). Screening for the Key Proteins Associated with Rete Testis Invasion in Clinical Stage I Seminoma via Label-Free Quantitative Mass Spectrometry. Cancers, 13.","DOI":"10.3390\/cancers13215573"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"161 e7","DOI":"10.1016\/j.urolonc.2017.10.028","article-title":"High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer","volume":"36","author":"Lobo","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/PAI.0b013e3181f05a66","article-title":"Immunohistochemistry Expression of P53, Ki67, CD30, and CD117 and Presence of Clinical Metastasis at Diagnosis of Testicular Seminoma","volume":"19","author":"Gallegos","year":"2011","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2003.07.169","article-title":"Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial","volume":"21","author":"Albers","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_21","first-page":"1710","article-title":"MIB-1 Immunohistochemistry in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors Predicts Patients at Low Risk for Metastasis","volume":"79","author":"Albers","year":"1996","journal-title":"Am. Cancer Soc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.canlet.2021.07.037","article-title":"The developmental origin of cancers defines basic principles of cisplatin resistance","volume":"519","author":"Skowron","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13148-021-01048-y","article-title":"Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples","volume":"13","author":"Lobo","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ajur.2020.05.009","article-title":"Molecular and epigenetic pathogenesis of germ cell tumors","volume":"8","author":"Muller","year":"2021","journal-title":"Asian J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Singh, R., Fazal, Z., Freemantle, S., and Spinella, M. (2021). Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors. Cancers, 13.","DOI":"10.3390\/cancers13071506"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Majello, B., Gorini, F., Sacc\u00e0, C.D., and Amente, S. (2019). Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer. Cancers, 11.","DOI":"10.3390\/cancers11030324"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ijc.25349","article-title":"Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers","volume":"128","author":"Hayami","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.bmc.2018.01.031","article-title":"New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells","volume":"26","author":"Hoang","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41585-019-0154-x","article-title":"Epigenetic drugs and their molecular targets in testicular germ cell tumours","volume":"16","author":"Jostes","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.humpath.2018.07.016","article-title":"Testicular germ cell tumors: Revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists","volume":"82","author":"Lobo","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lobo, J., Gillis, A.J.M., van den Berg, A., Dorssers, L.C.J., Belge, G., Dieckmann, K.P., Roest, H.P., van der Laan, L.J.W., Gietema, J., and Hamilton, R.J. (2019). Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells, 8.","DOI":"10.3390\/cells8121637"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lobo, J., Cardoso, A.R., Miranda-Goncalves, V., Looijenga, L.H.J., Lopez, M., Arimondo, P.B., Henrique, R., and Jeronimo, C. (2021). Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010073"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-021-02072-9","article-title":"The component of the m(6)A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors","volume":"40","author":"Lobo","year":"2021","journal-title":"J. Exp. Clin. Cancer. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.csbj.2021.01.022","article-title":"QuPath: The global impact of an open source digital pathology system","volume":"19","author":"Humphries","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/path.1711680404","article-title":"Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections","volume":"168","author":"Cattoretti","year":"1992","journal-title":"J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/1097-0142(19950201)75:3<844::AID-CNCR2820750316>3.0.CO;2-C","article-title":"lmmunohistochemical Assessment of Tumor Proliferationand Volume of Embryonal Carcinoma Identify Patients with Clinical Stage A Nonseminomatous Testicular Germ Cell Tumor at Low Risk for Occult Metastasis","volume":"75","author":"Albers","year":"1994","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00428-017-2258-0","article-title":"Ki67 labeling index: Assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms","volume":"472","author":"Kloppel","year":"2018","journal-title":"Virchows Arch."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.breast.2020.07.002","article-title":"Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer","volume":"53","author":"Serna","year":"2020","journal-title":"Breast"},{"key":"ref_40","first-page":"492","article-title":"Prognostic Significance of Immunohistochemical Proliferation Markers (Ki67\/MIB-1 and Proliferation-Associated Nuclear Antigen), p53 Protein Accumulation, and Neovascularization in Clinical Stage A Nonseminomatous Testicular Germ Cell Tumors","volume":"8","author":"Albers","year":"1995","journal-title":"Mod. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.celrep.2018.06.110","article-title":"Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence","volume":"24","author":"Miller","year":"2018","journal-title":"Cell Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","article-title":"Ki67 is a promising molecular target in the diagnosis of cancer (review)","volume":"11","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/1097-0142(19940815)74:4<1335::AID-CNCR2820740425>3.0.CO;2-T","article-title":"Predictive Parameters of Biologic Behavior of Early Stage Nonseminomatous Testicular Germ Cell Tumors","volume":"74","author":"Albers","year":"1994","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/jclinpath-2019-206205","article-title":"Good staining quality ensuring the reproducibility of Ki67 assessment","volume":"73","author":"Wang","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"ref_45","unstructured":"Backwell, W. (2017). Immunohistochemistry and Immunocytochemistry: Essential Methods, Wiley. [2nd ed.]."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4132\/jptm.2016.08.08","article-title":"Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips","volume":"50","author":"Kim","year":"2016","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1200\/JCO.2003.03.136","article-title":"Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor","volume":"21","author":"Mazumdar","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14737159.2018.1522252","article-title":"Tissue microarrays-translational biomarker research in the fast lane","volume":"18","author":"Behling","year":"2018","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00428-021-03194-3","article-title":"Morphological and molecular heterogeneity in testicular germ cell tumors: Implications for dedicated investigations","volume":"479","author":"Lobo","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00428-021-03168-5","article-title":"Gene expression microarray analysis of adult testicular germ cell tumor: A comparison between pure-type seminomas and seminoma components in mixed tumors","volume":"479","author":"Miyai","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.bbagrm.2013.05.002","article-title":"The histone LSD1 demethylase in stemness and cancer transcription programs","volume":"1829","author":"Amente","year":"2013","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Yang, G.J., Lei, P.M., Wong, S.Y., Ma, D.L., and Leung, C.H. (2018). Pharmacological Inhibition of LSD1 for Cancer Treatment. Molecules, 23.","DOI":"10.3390\/molecules23123194"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1158\/0008-5472.CAN-11-0896","article-title":"Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties","volume":"71","author":"Wang","year":"2011","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fendo.2012.00150","article-title":"Epigenetic: A molecular link between testicular cancer and environmental exposures","volume":"3","author":"Vega","year":"2012","journal-title":"Front. Endocrinol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/2\/264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:17:27Z","timestamp":1760134647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/2\/264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["life12020264"],"URL":"https:\/\/doi.org\/10.3390\/life12020264","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]}}}